NFATc1 and NFATc3 may serve as biomarkers for the characterization of NSCLC patients at risk for BM, and NFATc1 and NFATc3 might serve as targets for the treatment of NSCLC. Here, NFATC3 is linked to non-small cell lung carcinoma.